Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Thoracic Surgery

Free Subscription Articles published in Lancet Retrieve available abstracts of 39 articles: HTML format

Single Articles

December 2025
1. KEDHI E, Hermanides RS, Dambrink JE, Singh SK, et al
   TransCatheter aortic valve implantation and fractional flow reserve-guided percutaneous coronary intervention versus conventional surgical aortic valve replacement and coronary bypass grafting for treatment of patients with aortic valve stenosis and c
   Lancet. 2025;404:2593-2602.
   PubMed     Abstract available
   
   
   August 2025
2. VERMA S, Leiter LA, Teoh H, Mancini GBJ, et al
   Effect of evolocumab on saphenous vein graft patency after coronary artery bypass surgery (NEWTON-CABG CardioLink-5): an international, randomised, double-blind, placebo-controlled trial.
   Lancet. 2025 Aug 28:S0140-6736(25)01633-2. doi: 10.1016/S0140-6736(25)01633.
   PubMed     Abstract available
   
   
   
3. GAUDINO M, Sandner S
   Evolocumab for prevention of coronary artery bypass failure: timing is everything.
   Lancet. 2025 Aug 28:S0140-6736(25)01718-0. doi: 10.1016/S0140-6736(25)01718.
   PubMed    
   
   
   
4. KIM MC, Ahn JH, Hyun DY, Lim Y, et al
   Immediate versus staged complete revascularisation during index admission in patients with ST-segment elevation myocardial infarction and multivessel disease (OPTION-STEMI): a multicentre, non-inferiority, open-label, randomised trial.
   Lancet. 2025 Aug 28:S0140-6736(25)01529-6. doi: 10.1016/S0140-6736(25)01529.
   PubMed     Abstract available
   
   
   
5. CHENG SP, Chen PH, Jhou HJ
   Timing of cardiac surgery and anticoagulants after acute ischaemic stroke.
   Lancet. 2025;406:601.
   PubMed    
   
   
   
6. WERRING DJ, Dehbi HM, Best JG, Nash PS, et al
   Timing of cardiac surgery and anticoagulants after acute ischaemic stroke - Authors' reply.
   Lancet. 2025;406:601-602.
   PubMed    
   
   
   
7. POCAR M, Barbero C, Cerrato P, De Rosa FG, et al
   Timing of cardiac surgery and anticoagulants after acute ischaemic stroke.
   Lancet. 2025;406:600-601.
   PubMed    
   
   
   May 2025
8. MAKKAR RR, Ramana RK, Gnall E, Ramlawi B, et al
   ACURATE neo2 valve versus commercially available transcatheter heart valves in patients with severe aortic stenosis (ACURATE IDE): a multicentre, randomised, controlled, non-inferiority trial.
   Lancet. 2025 May 20:S0140-6736(25)00319-8. doi: 10.1016/S0140-6736(25)00319.
   PubMed     Abstract available
   
   
   April 2025
9. TERKELSEN CJ, Freeman P, Dahl JS, Thim T, et al
   SAPIEN 3 versus Myval transcatheter heart valves for transcatheter aortic valve implantation (COMPARE-TAVI 1): a multicentre, randomised, non-inferiority trial.
   Lancet. 2025;405:1362-1372.
   PubMed     Abstract available
   
   
   March 2025
10. CHOI KH, Park YH, Lee JY, Jeong JO, et al
    Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial.
    Lancet. 2025 Mar 28:S0140-6736(25)00449-0. doi: 10.1016/S0140-6736(25)00449.
    PubMed     Abstract available
    
    
    
11. FEARON WF, Zimmermann FM, Ding VY, Takahashi K, et al
    Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial.
    Lancet. 2025 Mar 28:S0140-6736(25)00505-7. doi: 10.1016/S0140-6736(25)00505.
    PubMed     Abstract available
    
    
    
12. HU X, Zhang J, Yang S, Jiang J, et al
    Angiography-derived fractional flow reserve versus intravascular ultrasound to guide percutaneous coronary intervention in patients with coronary artery disease (FLAVOUR II): a multicentre, randomised, non-inferiority trial.
    Lancet. 2025 Mar 28:S0140-6736(25)00504-5. doi: 10.1016/S0140-6736(25)00504.
    PubMed     Abstract available
    
    
    
13. TAM DY, Lee G, Chikwe J
    Fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting: please mind the gap.
    Lancet. 2025 Mar 28:S0140-6736(25)00583-5. doi: 10.1016/S0140-6736(25)00583.
    PubMed    
    
    
    
14. KIRTANE AJ, Genereux P, Lewis B, Shlofmitz RA, et al
    Orbital atherectomy versus balloon angioplasty before drug-eluting stent implantation in severely calcified lesions eligible for both treatment strategies (ECLIPSE): a multicentre, open-label, randomised trial.
    Lancet. 2025 Mar 28:S0140-6736(25)00450-7. doi: 10.1016/S0140-6736(25)00450.
    PubMed     Abstract available
    
    
    October 2024
15. ANDERSEN BK, Sejr-Hansen M, Maillard L, Campo G, et al
    Quantitative flow ratio versus fractional flow reserve for coronary revascularisation guidance (FAVOR III Europe): a multicentre, randomised, non-inferiority trial.
    Lancet. 2024 Oct 29:S0140-6736(24)02175-5. doi: 10.1016/S0140-6736(24)02175.
    PubMed     Abstract available
    
    
    
16. BECKER LM, Swaans MJ
    Present and future of functional measurements in coronary revascularisation.
    Lancet. 2024 Oct 29:S0140-6736(24)02367-5. doi: 10.1016/S0140-6736(24)02367.
    PubMed    
    
    
    
17. ERLINGE D, Andersson J, Frobert O, Tornerud M, et al
    Bioadaptor implant versus contemporary drug-eluting stent in percutaneous coronary interventions in Sweden (INFINITY-SWEDEHEART): a single-blind, non-inferiority, registry-based, randomised controlled trial.
    Lancet. 2024 Oct 25:S0140-6736(24)02227-X. doi: 10.1016/S0140-6736(24)02227.
    PubMed     Abstract available
    
    
    
18. CAPODANNO D
    Coronary stenting with bioadaptors.
    Lancet. 2024 Oct 25:S0140-6736(24)02359-6. doi: 10.1016/S0140-6736(24)02359.
    PubMed    
    
    
    
19. ZACHARIAS J, Pitsis A, Glauber M, Solinas M, et al
    Endoscopic cardiac surgery: the path less taken.
    Lancet. 2024 Oct 1:S0140-6736(24)02080-4. doi: 10.1016/S0140-6736(24)02080.
    PubMed    
    
    
    August 2024
20. HONG SJ, Lee SJ, Lee SH, Lee JY, et al
    Optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention for patients with complex lesions (OCCUPI): an investigator-initiated, multicentre, randomised, open-label, superiority trial in South Korea.
    Lancet. 2024 Aug 30:S0140-6736(24)01454-5. doi: 10.1016/S0140-6736(24)01454.
    PubMed     Abstract available
    
    
    
21. MAMAS MA, Mintz GS
    Optical coherence tomography imaging for complex percutaneous coronary intervention.
    Lancet. 2024 Aug 30:S0140-6736(24)01593-9. doi: 10.1016/S0140-6736(24)01593.
    PubMed    
    
    
    
22. GAO C, He X, Ouyang F, Zhang Z, et al
    Drug-coated balloon angioplasty with rescue stenting versus intended stenting for the treatment of patients with de novo coronary artery lesions (REC-CAGEFREE I): an open-label, randomised, non-inferiority trial.
    Lancet. 2024 Aug 30:S0140-6736(24)01594-0. doi: 10.1016/S0140-6736(24)01594.
    PubMed     Abstract available
    
    
    
23. REGA F, Lebreton G, Para M, Michel S, et al
    Hypothermic oxygenated perfusion of the donor heart in heart transplantation: the short-term outcome from a randomised, controlled, open-label, multicentre clinical trial.
    Lancet. 2024;404:670-682.
    PubMed     Abstract available
    
    
    
24. KITTLESON MM
    Extending the boundaries of organ preservation: hope for heart transplantation.
    Lancet. 2024;404:631-633.
    PubMed    
    
    
    June 2024
25. AKODAD M, Gall E
    New-generation Myval transcatheter heart valve in severe aortic stenosis.
    Lancet. 2024;403:2664-2665.
    PubMed    
    
    
    
26. MOHIUDDIN MM, Tully A, Singh AK, Galindo J, et al
    Possible causes of graft dysfunction in cardiac xenotransplantation - Authors' reply.
    Lancet. 2024;403:2594-2595.
    PubMed    
    
    
    
27. AI HS, Lei Y, Hu K
    Possible causes of graft dysfunction in cardiac xenotransplantation.
    Lancet. 2024;403:2593-2594.
    PubMed    
    
    
    May 2024
28. BAUMBACH A, van Royen N, Amat-Santos IJ, Hudec M, et al
    LANDMARK comparison of early outcomes of newer-generation Myval transcatheter heart valve series with contemporary valves (Sapien and Evolut) in real-world individuals with severe symptomatic native aortic stenosis: a randomised non-inferiority trial.
    Lancet. 2024 May 22:S0140-6736(24)00821-3. doi: 10.1016/S0140-6736(24)00821.
    PubMed     Abstract available
    
    
    April 2024
29. PRAZ F, Beyersdorf F, Haugaa K, Prendergast B, et al
    Valvular heart disease: from mechanisms to management.
    Lancet. 2024;403:1576-1589.
    PubMed     Abstract available
    
    
    
30. HAHN RT, Muraru D, Lindman BR, Delgado V, et al
    Heart valve disease: at the threshold of a new era in patient management.
    Lancet. 2024;403:1519-1522.
    PubMed    
    
    
    
31. LI X, Ge Z, Kan J, Anjum M, et al
    Intravascular ultrasound-guided versus angiography-guided percutaneous coronary intervention in acute coronary syndromes (IVUS-ACS): a two-stage, multicentre, randomised trial.
    Lancet. 2024 Apr 5:S0140-6736(24)00282-4. doi: 10.1016/S0140-6736(24)00282.
    PubMed     Abstract available
    
    
    
32. DEN DEKKER WK
    Is intravascular imaging the future of percutaneous coronary intervention?
    Lancet. 2024 Apr 5:S0140-6736(24)00430-6. doi: 10.1016/S0140-6736(24)00430.
    PubMed    
    
    
    
33. GE Z, Kan J, Gao X, Raza A, et al
    Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial.
    Lancet. 2024 Apr 5:S0140-6736(24)00473-2. doi: 10.1016/S0140-6736(24)00473.
    PubMed     Abstract available
    
    
    
34. PARK SJ, Ahn JM, Kang DY, Yun SC, et al
    Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial.
    Lancet. 2024 Apr 4:S0140-6736(24)00413-6. doi: 10.1016/S0140-6736(24)00413.
    PubMed     Abstract available
    
    
    
35. BOROVAC JA
    Percutaneous coronary intervention for non-obstructive vulnerable plaques.
    Lancet. 2024 Apr 4:S0140-6736(24)00488-4. doi: 10.1016/S0140-6736(24)00488.
    PubMed    
    
    
    March 2024
36. WERNLY B, Jung C
    Transfemoral transcatheter aortic valve replacement for pure aortic regurgitation.
    Lancet. 2024 Mar 26:S0140-6736(24)00062-X. doi: 10.1016/S0140-6736(24)00062.
    PubMed    
    
    
    
37. VAHL TP, Thourani VH, Makkar RR, Hamid N, et al
    Transcatheter aortic valve implantation in patients with high-risk symptomatic native aortic regurgitation (ALIGN-AR): a prospective, multicentre, single-arm study.
    Lancet. 2024 Mar 26:S0140-6736(23)02806-4. doi: 10.1016/S0140-6736(23)02806.
    PubMed     Abstract available
    
    
    
38. LEBRETON G, Leprince P
    Successful heart transplant after 12 h preservation aboard a commercial flight.
    Lancet. 2024;403:1019.
    PubMed    
    
    
    February 2024
39. LEE ZS, Ryan N
    Intravascular imaging in percutaneous coronary intervention.
    Lancet. 2024 Feb 21:S0140-6736(23)02686-7. doi: 10.1016/S0140-6736(23)02686.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Thoracic Surgery is free of charge.